DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Hijioka S, Hosoda W, Matsuo K. et al.
Rb Loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3: a Japanese multicenter pancreatic NEN-G3 study.
Clin Cancer Res 2017;
23 (16) 4625-4632
We do not assume any responsibility for the contents of the web pages of other providers.